{"transactions":[{"id":762662,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-CHIEF DEVELOPMENT OFFICER"}}],"security":"Common Stock","published_at":"2026-05-27T23:30:09.000Z","date":"2026-05-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":4036,"price":0.1743,"value":703.4748,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of an RSU grant that vested on May 25, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 25, 2026 of $0.1743/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: 7,214 shares from the May 25, 2026 vesting installment of the Reporting Person's February 25, 2025 RSU grant and the remaining 78,750 shares will vest in 7 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":328733,"source":{"system":"sec-edgar","filing":"0001947007-26-000012","document":"form4-05272026_070505.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000194700726000012/form4-05272026_070505.xml","form_type":"4"}},{"id":802122,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-CHIEF DEVELOPMENT OFFICER"}}],"security":"Common Stock","published_at":"2026-04-23T20:05:40.000Z","date":"2026-04-21","kind":"sale","planned":false,"acquired":false,"shares":345942,"price":0.2578,"value":89183.8476,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $0.2533 to $0.2634, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":332769,"source":{"system":"sec-edgar","filing":"0001947007-26-000010","document":"form4-04232026_080436.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000194700726000010/form4-04232026_080436.xml","form_type":"4"}},{"id":817536,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-CHIEF DEVELOPMENT OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-03T20:15:20.000Z","date":"2026-04-01","kind":"grant","planned":false,"acquired":true,"shares":800000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":800000,"derivative":{"exercise_price":0.2601,"expiration_date":"2036-03-31","underlying":"Common Stock","underlying_shares":800000},"source":{"system":"sec-edgar","filing":"0001947007-26-000006","document":"form4-04032026_040403.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000194700726000006/form4-04032026_040403.xml","form_type":"4"}},{"id":880421,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-CHIEF DEVELOPMENT OFFICER"}}],"security":"Common Stock","published_at":"2026-02-27T02:40:15.000Z","date":"2026-02-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":12354,"price":0.47,"value":5806.38,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares underlying the portion of an RSU grant that vested on February 25, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 25, 2026 of $0.47/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes: 17,646 shares from the February 25, 2026 vesting installment of the Reporting Person's February 25, 2025 RSU grant and the remaining 90,000 shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is\nsubject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":678711,"source":{"system":"sec-edgar","filing":"0001947007-26-000004","document":"form4-02262026_090211.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000194700726000004/form4-02262026_090211.xml","form_type":"4"}},{"id":880420,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-CHIEF DEVELOPMENT OFFICER"}}],"security":"Common Stock","published_at":"2026-02-27T02:40:15.000Z","date":"2026-02-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":2063,"price":0.4725,"value":974.7675,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on February 24, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 24, 2026 of $0.4725/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 2,947 shares from the February 24, 2026 vesting installment of the Reporting Person's February 24, 2023 RSU grant and (b) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares subject to the grant on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":691065,"source":{"system":"sec-edgar","filing":"0001947007-26-000004","document":"form4-02262026_090211.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000194700726000004/form4-02262026_090211.xml","form_type":"4"}},{"id":931453,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-CHIEF DEVELOPMENT OFFICER"}}],"security":"Common Stock","published_at":"2026-01-26T21:06:47.000Z","date":"2026-01-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":36676,"price":0.3985,"value":14615.386,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on January 22, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on January 22, 2026 of $0.3985/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 52,387 shares from the January 22, 2026 vesting installment of the Reporting Person's January 22, 2024 RSU grant, (b) 5,010 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares subject to the grant on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 5,000 shares acquired on May 30, 2025 and 5,000 shares acquired on November 28, 2025 under the Issuer's 2020 Employee Stock Purchase Plan."}],"balance_after":693128,"source":{"system":"sec-edgar","filing":"0001947007-26-000002","document":"form4-01262026_090143.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000194700726000002/form4-01262026_090143.xml","form_type":"4"}},{"id":987862,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-CHIEF DEVELOPMENT OFFICER"}}],"security":"Common Stock","published_at":"2025-11-26T21:06:19.000Z","date":"2025-11-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":2544,"price":0.4166,"value":1059.8304,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on November 24, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on November 24, 2025 of $0.4166/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: 2,466 shares resulting from the November 24, 2025 vesting installment of the Reporting Person's\nFebruary 24, 2023 RSU grant, and the remaining 5,010 shares will vest on February 24, 2026, (b) 89,063 shares subject to Reporting Person's January 22, 2024 RSU grant will vest in successive equal quarterly installments through January 22, 2026, (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares subject to the grant on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":719804,"source":{"system":"sec-edgar","filing":"0001947007-25-000006","document":"form4-11262025_091116.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000194700725000006/form4-11262025_091116.xml","form_type":"4"}},{"id":1013993,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-CHIEF DEVELOPMENT OFFICER"}}],"security":"Common Stock","published_at":"2025-10-24T21:00:14.000Z","date":"2025-10-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":43741,"price":0.66,"value":28869.06,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on October 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on October 22, 2025 of $0.66/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 45,321 shares resulting from the October 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 89,063 shares will vest in successive equal quarterly installments through January 22, 2026, (b) 10,020 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares subject to the grant on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":722348,"source":{"system":"sec-edgar","filing":"0001947007-25-000004","document":"form4-10242025_051010.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000194700725000004/form4-10242025_051010.xml","form_type":"4"}},{"id":1056133,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-CHIEF DEVELOPMENT OFFICER"}}],"security":"Common Stock","published_at":"2025-08-26T23:59:09.000Z","date":"2025-08-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":1792,"price":0.5863,"value":1050.6496,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on August 24, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on August 22, 2025 of $0.5863/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 3,218 shares resulting from the August 24, 2025 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 10,020 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 178,125 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":766089,"source":{"system":"sec-edgar","filing":"0001415889-25-023071","document":"form4-08262025_110806.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000141588925023071/form4-08262025_110806.xml","form_type":"4"}},{"id":1082412,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-CHIEF DEVELOPMENT OFFICER"}}],"security":"Common Stock","published_at":"2025-07-24T20:56:27.000Z","date":"2025-07-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":31866,"price":0.4798,"value":15289.3068,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on July 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on July 22, 2025 of $0.4798/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 57,197 shares resulting from the July 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 178,125 shares will vest in successive equal quarterly installments through January 22, 2026, (b) 15,030 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares subject to the grant on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":767881,"source":{"system":"sec-edgar","filing":"0001415889-25-020243","document":"form4-07242025_080724.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000141588925020243/form4-07242025_080724.xml","form_type":"4"}},{"id":1132473,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-CHIEF DEVELOPMENT OFFICER"}}],"security":"Common Stock","published_at":"2025-05-28T20:05:09.000Z","date":"2025-05-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":1792,"price":0.4733,"value":848.1536,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on May 24, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 23, 2025 of $0.4733/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 3,217 shares resulting from the May 24, 2025 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 15,030 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 267,188 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":799747,"source":{"system":"sec-edgar","filing":"0001415889-25-014694","document":"form4-05282025_040506.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000141588925014694/form4-05282025_040506.xml","form_type":"4"}},{"id":1166723,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-CHIEF DEVELOPMENT OFFICER"}}],"security":"Common Stock","published_at":"2025-04-24T20:07:02.000Z","date":"2025-04-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":31866,"price":0.7763,"value":24737.5758,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on April 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on April 22, 2025 of $0.7763/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 57,196 shares resulting from the April 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 267,188 shares will vest in successive equal quarterly installments through January 22, 2026, (b) 20,039 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares subject to the grant on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":801539,"source":{"system":"sec-edgar","filing":"0001415889-25-011281","document":"form4-04242025_080459.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000141588925011281/form4-04242025_080459.xml","form_type":"4"}},{"id":1244037,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-CHIEF DEVELOPMENT OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-26T22:32:37.000Z","date":"2025-02-25","kind":"grant","planned":false,"acquired":true,"shares":560000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":560000,"derivative":{"exercise_price":0.9561,"expiration_date":"2035-02-24","underlying":"Common Stock","underlying_shares":560000},"source":{"system":"sec-edgar","filing":"0001415889-25-005707","document":"form4-02262025_100233.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000141588925005707/form4-02262025_100233.xml","form_type":"4"}},{"id":1244036,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-CHIEF DEVELOPMENT OFFICER"}}],"security":"Common Stock","published_at":"2025-02-26T22:32:37.000Z","date":"2025-02-25","kind":"grant","planned":false,"acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Represents shares of common stock issuable upon settlement of a RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Includes: (a) 20,039 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026, (b) 356,250 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":833405,"source":{"system":"sec-edgar","filing":"0001415889-25-005707","document":"form4-02262025_100233.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000141588925005707/form4-02262025_100233.xml","form_type":"4"}},{"id":1244035,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-CHIEF DEVELOPMENT OFFICER"}}],"security":"Common Stock","published_at":"2025-02-26T22:32:37.000Z","date":"2025-02-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":1513,"price":0.9561,"value":1446.5793,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares underlying the portion of an RSU grant that vested on February 25, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 25, 2025 of $0.9561/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes: (a) 2,716 shares resulting from the February 25, 2025 final vesting installment of the Reporting Person's February 25, 2022 RSU grant, (b) 20,039 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 356,250 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":713405,"source":{"system":"sec-edgar","filing":"0001415889-25-005707","document":"form4-02262025_100233.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000141588925005707/form4-02262025_100233.xml","form_type":"4"}},{"id":1244034,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-CHIEF DEVELOPMENT OFFICER"}}],"security":"Common Stock","published_at":"2025-02-26T22:32:37.000Z","date":"2025-02-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":1792,"price":1,"value":1792.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on February 24, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 24, 2025 of $1.00/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 3,218 shares resulting from the February 24, 2025 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 20,039 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 4,229 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in one final installment on February 25, 2025, and (c) 356,250 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":714918,"source":{"system":"sec-edgar","filing":"0001415889-25-005707","document":"form4-02262025_100233.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000141588925005707/form4-02262025_100233.xml","form_type":"4"}},{"id":1295889,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-CHIEF DEVELOPMENT OFFICER"}}],"security":"Common Stock","published_at":"2025-01-24T21:05:15.000Z","date":"2025-01-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":129593,"price":1.15,"value":149031.95,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on January 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on January 22, 2025 of $1.15/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 226,657 shares resulting from the January 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 356,250 shares will vest in successive equal quarterly installments through January 22, 2026, (b) 4,229 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in one final installment on February 25, 2025 and (c) 25,049 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026.  The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 5,000 shares acquired on November 29, 2024 under the Issuer's 2020 Employee Stock Purchase Plan."}],"balance_after":716710,"source":{"system":"sec-edgar","filing":"0001415889-25-002020","document":"form4-01242025_040107.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000141588925002020/form4-01242025_040107.xml","form_type":"4"}},{"id":1351552,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-CHIEF DEVELOPMENT OFFICER"}}],"security":"Common Stock","published_at":"2024-11-26T21:08:45.000Z","date":"2024-11-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":1508,"price":1.94,"value":2925.52,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares underlying the portion of an RSU grant that vested on November 25, 2024, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on November 25, 2024 of $1.94/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes: (a) 2,720 shares resulting from the November 25, 2024 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 4,229 shares will vest in one final installment on February 25, 2025, (b) 25,049 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 712,500 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter."}],"balance_after":841303,"source":{"system":"sec-edgar","filing":"0001415889-24-027704","document":"form4-11262024_091141.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000141588924027704/form4-11262024_091141.xml","form_type":"4"}},{"id":1351551,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-CHIEF DEVELOPMENT OFFICER"}}],"security":"Common Stock","published_at":"2024-11-26T21:08:45.000Z","date":"2024-11-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":1787,"price":1.88,"value":3359.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on November 24, 2024, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on November 22, 2024 of $1.88/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 3,223 shares resulting from the November 24, 2024 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 25,049 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 8,457 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in successive equal quarterly installments through February 25, 2025, and (c) 712,500 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":842811,"source":{"system":"sec-edgar","filing":"0001415889-24-027704","document":"form4-11262024_091141.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000141588924027704/form4-11262024_091141.xml","form_type":"4"}},{"id":1422375,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-CHIEF DEVELOPMENT OFFICER"}}],"security":"Common Stock","published_at":"2024-08-27T20:37:08.000Z","date":"2024-08-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":1508,"price":0.86,"value":1296.88,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Represents shares underlying the portion of an RSU grant that vested on August 25, 2024, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on August 23, 2024 of $0.86/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Includes: (a) 2,720 shares resulting from the August 25, 2024 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 8,457 shares will vest in successive equal quarterly installments through February 25, 2025, (b) 30,059 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 712,500 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter."}],"balance_after":844598,"source":{"system":"sec-edgar","filing":"0001415889-24-022307","document":"form4-08272024_080803.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000141588924022307/form4-08272024_080803.xml","form_type":"4"}},{"id":1422374,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-CHIEF DEVELOPMENT OFFICER"}}],"security":"Common Stock","published_at":"2024-08-27T20:37:08.000Z","date":"2024-08-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":1787,"price":0.86,"value":1536.82,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on August 24, 2024, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on August 23, 2024 of $0.86/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 3,223 shares resulting from the August 24, 2024 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 30,059 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 12,685 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in successive equal quarterly installments through February 25, 2025, and (c) 712,500 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 5,000 shares acquired on May 31, 2024 under the Issuer's 2020 Employee Stock Purchase Plan."}],"balance_after":846106,"source":{"system":"sec-edgar","filing":"0001415889-24-022307","document":"form4-08272024_080803.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000141588924022307/form4-08272024_080803.xml","form_type":"4"}},{"id":1499542,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-CHIEF DEVELOPMENT OFFICER"}}],"security":"Common Stock","published_at":"2024-05-29T21:18:02.000Z","date":"2024-05-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":1508,"price":0.6,"value":904.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares underlying the portions of RSU grants that vested on May 25, 2024, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 24, 2024 of $0.60/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes: (a) 2,720 shares resulting from the May 25, 2024 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 12,685 shares will vest in successive equal quarterly installments through February 25, 2025, (b) 35,069 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 712,500 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter."}],"balance_after":842893,"source":{"system":"sec-edgar","filing":"0001415889-24-014798","document":"form4-05292024_090558.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000141588924014798/form4-05292024_090558.xml","form_type":"4"}},{"id":1499541,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-CHIEF DEVELOPMENT OFFICER"}}],"security":"Common Stock","published_at":"2024-05-29T21:18:02.000Z","date":"2024-05-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":1787,"price":0.6,"value":1072.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portions of RSU grants that vested on May 24, 2024, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 24, 2024 of $0.60/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 3,222 shares resulting from the May 24, 2024 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 35,069 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 16,913 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in successive equal quarterly installments through February 25, 2025, and (c) 712,500 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":844401,"source":{"system":"sec-edgar","filing":"0001415889-24-014798","document":"form4-05292024_090558.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000141588924014798/form4-05292024_090558.xml","form_type":"4"}},{"id":1616998,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-CHIEF DEVELOPMENT OFFICER"}}],"security":"Common Stock","published_at":"2024-02-27T22:13:14.000Z","date":"2024-02-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":5010,"price":1.13,"value":5661.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares underlying the portions of RSU grants that vested on February 25, 2024, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 23, 2024 of $1.13/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes: (a) 4,723 shares resulting from the February 25, 2024 final vesting installment of the Reporting Person's February 25, 2021 RSU grant, (b) 2,496 shares resulting from the February 25, 2024 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 16,913 shares will vest in successive equal quarterly installments through February 25, 2025, (c) 40,078 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (d) 712,500 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter."}],"balance_after":846188,"source":{"system":"sec-edgar","filing":"0001415889-24-005549","document":"form4-02272024_100209.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000141588924005549/form4-02272024_100209.xml","form_type":"4"}},{"id":1616997,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-CHIEF DEVELOPMENT OFFICER"}}],"security":"Common Stock","published_at":"2024-02-27T22:13:14.000Z","date":"2024-02-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":5474,"price":1.13,"value":6185.62,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portions of RSU grants that vested on February 24, 2024, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 23, 2024 of $1.13/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 7,886 shares resulting from the February 24, 2024 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 40,078 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 8,001 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024, (c) 21,141 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in successive equal quarterly installments through February 25, 2025, and (d) 712,500 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":851198,"source":{"system":"sec-edgar","filing":"0001415889-24-005549","document":"form4-02272024_100209.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000141588924005549/form4-02272024_100209.xml","form_type":"4"}},{"id":1672347,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-CHIEF DEVELOPMENT OFFICER"}}],"security":"Common Stock","published_at":"2024-01-24T21:40:39.000Z","date":"2024-01-22","kind":"grant","planned":false,"acquired":true,"shares":712500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issuable upon settlement of a restricted stock unit (\"RSU\") grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\")) through each such date and subject to acceleration in full in the event of a Change in Control (as defined in the 2018 EIP)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 8,001 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024, (b) 21,141 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in successive equal quarterly installments through February 25, 2025, and (c) 53,438 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 5,000 shares acquired on November 30, 2023 under the Issuer's 2020 Employee Stock Purchase Plan."}],"balance_after":856672,"source":{"system":"sec-edgar","filing":"0001415889-24-001755","document":"form4-01242024_090133.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000141588924001755/form4-01242024_090133.xml","form_type":"4"}},{"id":1728965,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-Chief Development Officer"}}],"security":"Common Stock","published_at":"2023-11-28T21:16:54.000Z","date":"2023-11-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":1462,"price":0.3821,"value":558.6302,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on November 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on November 24, 2023 of $0.3821/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 2,766 shares resulting from the November 25, 2023 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 21,141 shares will vest in successive equal quarterly installments through February 25, 2025, (b) 8,001 shares subject to Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024 and (c) 53,438 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter.  The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":139172,"source":{"system":"sec-edgar","filing":"0001209191-23-056777","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000120919123056777/doc4.xml","form_type":"4"}},{"id":1794521,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-Chief Development Officer"}}],"security":"Common Stock","published_at":"2023-08-29T20:13:03.000Z","date":"2023-08-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":1462,"price":0.77,"value":1125.74,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on August 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on August 25, 2023 of $0.77/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 2,766 shares resulting from the August 25, 2023 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 25,369 shares will vest in successive equal quarterly installments through February 25, 2025, (b) 8,001 shares subject to Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024 and (c) 53,438 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter.  The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 5,000 shares acquired on May 31, 2023 under the Issuer's 2020 Employee Stock Purchase Plan."}],"balance_after":140634,"source":{"system":"sec-edgar","filing":"0001209191-23-047579","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000120919123047579/doc4.xml","form_type":"4"}},{"id":1875348,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-Chief Development Officer"}}],"security":"Common Stock","published_at":"2023-05-30T20:43:01.000Z","date":"2023-05-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":1462,"price":1.33,"value":1944.46,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on May 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 25, 2023 of $1.33/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 2,766 shares resulting from the May 25, 2023 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 29,597 shares will vest in successive equal quarterly installments through February 25, 2025, (b) 8,001 shares subject to Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024 and (c) 53,438 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter.  The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":137096,"source":{"system":"sec-edgar","filing":"0001209191-23-032909","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000120919123032909/doc4.xml","form_type":"4"}},{"id":1970060,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-Chief Development Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-06T22:08:32.000Z","date":"2023-02-24","kind":"grant","acquired":true,"shares":249375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":249375,"derivative":{"exercise_price":2.66,"expiration_date":"2033-02-23","underlying":"Common Stock","underlying_shares":249375},"source":{"system":"sec-edgar","filing":"0001209191-23-016393","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000120919123016393/doc4.xml","form_type":"4"}},{"id":1970059,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-Chief Development Officer"}}],"security":"Common Stock","published_at":"2023-03-06T22:08:32.000Z","date":"2023-02-25","kind":"tax_withholding","acquired":false,"shares":9834,"price":2.66,"value":26158.44,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares underlying the portions of RSU grants that vested on February 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 24, 2023 of $2.66/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes: (a) 5,998 shares resulting from the February 25, 2023 final vesting installment of the Reporting Person's February 25, 2020 RSU grant, (b) 5,233 shares resulting from the February 25, 2023 vesting installment of the Reporting Person's February 25, 2021 RSU grant and 8,001 shares subject to such RSU grant that will vest in one final installment on February 25, 2024 and (c) 7,377 shares resulting from the February 25, 2023 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 33,825 shares will vest in 8 successive equal quarterly installments thereafter.  The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":138558,"source":{"system":"sec-edgar","filing":"0001209191-23-016393","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000120919123016393/doc4.xml","form_type":"4"}},{"id":1970058,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-Chief Development Officer"}}],"security":"Common Stock","published_at":"2023-03-06T22:08:32.000Z","date":"2023-02-24","kind":"grant","acquired":true,"shares":53438,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issuable upon settlement of a restricted stock unit (\"RSU\") grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\")) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":148392,"source":{"system":"sec-edgar","filing":"0001209191-23-016393","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000120919123016393/doc4.xml","form_type":"4"}}]}